7:00 AM ET
8-K
Business Update
Biohaven Business Update
Biohaven announced that the FDA has accepted its New Drug Application (NDA) resubmission for Vyglxia (troriluzole) for the treatment of spinocerebellar ataxia (SCA). The FDA has assigned a user fee goal date in the first quarter of 2027 and plans to convene an advisory committee meeting to review the application.
- Counterparty
- FDA